These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 14669287)
1. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287 [TBL] [Abstract][Full Text] [Related]
2. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Louafi S; Boige V; Ducreux M; Bonyhay L; Mansourbakht T; de Baere T; Asnacios A; Hannoun L; Poynard T; Taïeb J Cancer; 2007 Apr; 109(7):1384-90. PubMed ID: 17330837 [TBL] [Abstract][Full Text] [Related]
3. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Asnacios A; Fartoux L; Romano O; Tesmoingt C; Louafi S S; Mansoubakht T; Artru P; Poynard T; Rosmorduc O; Hebbar M; Taieb J Cancer; 2008 Jun; 112(12):2733-9. PubMed ID: 18412149 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. Zhu AX; Blaszkowsky LS; Ryan DP; Clark JW; Muzikansky A; Horgan K; Sheehan S; Hale KE; Enzinger PC; Bhargava P; Stuart K J Clin Oncol; 2006 Apr; 24(12):1898-903. PubMed ID: 16622265 [TBL] [Abstract][Full Text] [Related]
5. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Liu Y; Yue H; Xu S; Wang F; Ma N; Li K; Qiao L; Wang J Int J Clin Oncol; 2015 Oct; 20(5):952-9. PubMed ID: 25712158 [TBL] [Abstract][Full Text] [Related]
6. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ; J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience. Li J; Merl M; Lee MX; Kaley K; Saif MW Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915 [TBL] [Abstract][Full Text] [Related]
8. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C; Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238 [TBL] [Abstract][Full Text] [Related]
9. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial. Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198 [TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Patrikidou A; Sinapi I; Regnault H; Fayard F; Bouattour M; Fartoux L; Faivre S; Malka D; Ducreux M; Boige V Invest New Drugs; 2014 Oct; 32(5):1028-35. PubMed ID: 24748335 [TBL] [Abstract][Full Text] [Related]
11. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis. Dhooge M; Coriat R; Mir O; Perkins G; Brezault C; Boudou-Rouquette P; Goldwasser F; Chaussade S Oncology; 2013; 84(1):32-8. PubMed ID: 23076239 [TBL] [Abstract][Full Text] [Related]
12. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Skarlos D Ann Oncol; 2004 Mar; 15(3):493-7. PubMed ID: 14998855 [TBL] [Abstract][Full Text] [Related]
13. Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16). Park I; Kim BS; Lim HY; Kim HJ; Lee HJ; Choi YJ; Park KH; Lee KH; Yoon S; Hong B; Hong JH; Ahn H; Lee JL Eur J Cancer; 2020 Mar; 127():183-190. PubMed ID: 31668839 [TBL] [Abstract][Full Text] [Related]
14. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. Vici P; Sergi D; Pizzuti L; Mariani L; Arena MG; Barba M; Maugeri-Saccà M; Vincenzoni C; Vizza E; Corrado G; Paoletti G; Tomao F; Tomao S; Giannarelli D; Di Lauro L J Exp Clin Cancer Res; 2013 Aug; 32(1):49. PubMed ID: 23927758 [TBL] [Abstract][Full Text] [Related]
15. [Efficacy of gemcitabine combined oxaliplatin on advanced pancreatic cancer]. Shi YX; Xu RH; Jiang WQ; Zhang L; Lin TY; Li YH; Xia ZJ; Luo HY; Han B; Wang F; He YJ; Guan ZZ Ai Zheng; 2007 Dec; 26(12):1381-4. PubMed ID: 18076807 [TBL] [Abstract][Full Text] [Related]
16. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy. Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. Zaanan A; Williet N; Hebbar M; Dabakuyo TS; Fartoux L; Mansourbakht T; Dubreuil O; Rosmorduc O; Cattan S; Bonnetain F; Boige V; Taïeb J J Hepatol; 2013 Jan; 58(1):81-8. PubMed ID: 22989572 [TBL] [Abstract][Full Text] [Related]
18. Treatment of advanced hepatocellular carcinoma with gemcitabine plus oxaliplatin. Li S; Niu Z; Tian H; Zhang B; Wang F; Yi LH; Yu J Hepatogastroenterology; 2007; 54(73):218-23. PubMed ID: 17419264 [TBL] [Abstract][Full Text] [Related]
19. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Corazzelli G; Capobianco G; Arcamone M; Ballerini PF; Iannitto E; Russo F; Frigeri F; Becchimanzi C; Marcacci G; De Chiara A; Pinto A Cancer Chemother Pharmacol; 2009 Oct; 64(5):907-16. PubMed ID: 19219604 [TBL] [Abstract][Full Text] [Related]
20. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. Fortune BE; Li X; Kosuri KV; Weatherby LM; Thomas JP; Bekaii-Saab TS Oncology; 2009; 76(5):333-7. PubMed ID: 19307739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]